Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of temsirolimus when given together
with brentuximab vedotin in treating patients with Hodgkin lymphoma that has returned or has
not responded to treatment. Temsirolimus may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. Biological therapies, such as brentuximab vedotin, may
stimulate the immune system in different ways and stop cancer cells from growing. Giving
temsirolimus with brentuximab vedotin may work better in treating patients with Hodgkin
lymphoma.